AWN: 34521103 Filename: 34521103_	_Sojourn250ml_SG	iP_INS_11_22.ir	ndd		Proof#: 2
Artist/Date: Rashmi K, VD 25 Nov 2022 Reason for Revision: Addition of "Bradycardia in Down Syndrome Font Set & min. size: Brand Name-Swis721 Cn BT-Bold-16pt	RAG Vers.: n/a 2" information	Market: Material #: Superceded Mat.#: GTIN:	Singapore 20715863 n/a n/a	Die Line - No Print	n/a
Notes: Swis721 Cn BT-Roman-7pt, 12pt		MAH: Superceded AWN:	PCC Inc. 34521102	n/a	n/a n/a
Piramal Critical Care Created by: Regulatory Affairs, Global Labeling & Artwork Kamani, Kurla (W), 400078 ph: +91 (0))2238023535	Insert Size: 8 x 18 inches		n/a	n/a

Sojourn

Sevoflurane, USP Inhalation Anaesthetic

Description and Composition:

fluoromethoxypropane and has the following structural formula:

Some physical constants of Sevoflurane are: Relative molecular mass 200.05 Boiling point at 760mmHg 58.6°C 1.2740-1.2760 Refractive index n20 Specific gravity at 20°C 1.520-1.525

Vapor pressure Temn°C mmHa 20 157 25 197 36 317

Partition coefficients at 37°C

Water/Gas 0.36 0.63-0.69 Blood/Gas Olive Oil/Gas 47.2-53.9

Mean partition coefficients at 25°C - component/gas Conductive rubber 14.0 Butyl rubber 17.4 Polyvinylchloride 1.3

99.975% or better Purity by gas chromatography Flammability Not flammable

Sevoflurane contains only Sevoflurane, no additives are included.

Polyethylene

subsequent degradant formation are enhanced by increasing absorbent temperature desiccated CO₂ concentrations of up to 8% Sevoflurane may be used. absorbents (especially with potassium hydroxide-containing), increased sevoflurane concentration and decreased fresh gas flow.

Sevoflurane can undergo alkaline degradation by two pathways. The first results from the loss of commonly know as Compound A). The second pathway for degradation of sevoflurane occurs to maintain surgical anaesthesia. See above for MAC values. only in the presence of desiccated CO₂ absorbents and leads to the dissociation of sevoflurane into hexafluoroisopropanol (HFIP) and formaldehyde. HFIP is inactive, non-genotoxic, rapidly Emergence: Emergence times are generally short following Sevoflurane anaesthesia. Therefore, glucoronidated, cleared and has toxicity comparable to sevoflurane. Formaldehyde is present during patients may require early post-operative pain relief. normal metabolic processes. Upon exposure to a highly desiccated absorbent, formaldehyde can further degrade into methanol and formate. Formate can contribute to the formation of carbon. Contraindications monoxide, in the presence of high temperature. Methanol can react with Compound A to form the Sevoflurane should not be used in patients with known or suspected sensitivity to Sevoflurane or to

hydroxide, the formation of formaldehyde, methanol, carbon monoxide, Compound A and perhaps of these agents). some of its degradants, Compounds B, C, and D may occur.

For induction and maintenance of general anaesthesia in-patient and out-patient surgery in both adults and children

Sevoflurane is a nonflammable, pleasant smelling, volatile liquid. It is 1,1,1,3,3,3-hexafluoro-2- Actions: The depth of anaesthesia changes rapidly following changes in the inspired concentration of Sevoflurane. Emergence and recovery are particularly rapid. Therefore, patients may require early assisted. post-operative pain relief.

> mean arterial pressure, but there was no change in heart rate. Sevoflurane did not alter plasma noradrenaline concentrations in this study.

No evidence of seizure was observed during the clinical development programme.

Dosage and Administration

Vaporisers specifically calibrated for use with Sevoflurane should be used so that the concentration delivered can be accurately controlled. MAC (minimum alveolar concentration) value for Sevoflurane related to depth of anaesthesia and in such instances may be corrected by decreasing the inspired decrease with age and with the addition of nitrous oxide. The table below indicates average MAC values for different age groups.

EFFECT OF AGE ON MAC OF SEVOFLURANE

AGE OF PATIENT	SEVOFLURANE	SEVOFLURANE IN
(YEARS)	IN OXYEGEN	65% N ₂ O / 35% O ₂ *
<3	3.3 - 2.6%	2.0%
3 - < 5	2.5%	Not available
5 - 12	2.4%	Not available
25	2.5%	1.4%
35	2.2%	1.2%
40	2.05%	1.1%
50	1.8%	0.98%
60	1.6%	0.87%
80	1.4%	0.70%

*In paediatric patients 60% N₂O / 40% O₂ was used.

Premedication: Premedication should be selected according to the need of the individual patient. and at the discretion of the anaesthetist. The use of anticholinergic drugs is a matter of choice.

Sevoflurane is stable when stored under normal room lighting conditions. No discernible degradation Induction: Anaesthesia can be induced in adults and children with Sevoflurane. Dosage should be of sevoflurane occurs in the presence of strong acids or heat. Sevoflurane is not corrosive to individualized and titrated to the desired effect according to the patients's age and clinical status. stainless steel, brass, aluminum, nickel-plated brass, chrome-plated brass, or copper beryllium A short acting barbiturate or other intravenous induction agent may be administered followed by inhalation of Sevoflurane. (See also "Interactions"). Induction with Sevoflurane may be achieved in oxygen or in combination with oxygen-nitrous oxide mixtures. In adults inspired concentrations Chemical degradation can occur upon exposure of inhaled anaesthetics to CO₂ absorbent within of up to 5% Sevoflurane usually produce surgical anaesthesia in less than 2 minutes. In children, the anesthesia machine. When used as directed with fresh absorbents, degradation sevoflurane inspired concentrations of up to 7% Sevoflurane usually produce surgical anaesthesia in less is minimal, and degradants are either undetectable or non-toxic. Sevoflurane degradation and than 2 minutes. Alternatively, for induction of anaesthesia in unpremedicated patients, inspired

> **Maintenance:** Surgical levels of anaesthesia may be sustained with concentrations of 0.5 - 3% and hypovolemia. Sevoflurane with or without the concomitant use of nitrous oxide (see also "Drug Interactions").

hydrogen fluoride with the formation of pentafluoroisopropanyl fluoromethyl ether (PIFE or more Elderly: As with other inhalation agents, lesser concentrations of Sevoflurane are normally required postmarketing reports of malignant hyperthermia. Some of these cases have been fatal.

methoxy addition product Compound B. Compound B can undergo further HF elimination to form other halogenated inhalational anaesthetics (e.g., history of hepatotoxicity, usually including elevated Compounds C, D, and E. With highly desiccated absorbents, especially those containing potassium liver enzymes, fever, leukocytosis and/or eosinophilia temporally related to anaesthesia with one Perioperative Hyperkalemia: Use of inhaled anaesthetic agents has been associated with

Sevoflurane is also contraindicated in patients known or suspected genetic susceptibility to malignant hyperthermia.

Warnings and Precautions

or other agents causing respiratory depression. Respiration should be supervised and if necessary,

Sevoflurane should be administered only by persons trained in the administration of general Renal Impairment: Because of the small number of patients with renal insufficiency (baseline As with all other inhalation agents Sevoflurane depresses cardiovascular function in a dose related anaesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment serum creatinine greater than 133 micromol / litre) studied, the safety of Sevoflurane administration fashion. In one volunteer study, increases in Sevoflurane concentration resulted in decrease in and circulatory resuscitation must be immediately available. The concentration of sevoflurane being in this group has not been fully established. Therefore, Sevoflurane should be used with caution in delivered from a vaporizer must be known exactly. As volatile anaesthetics differ in their physical patients with renal insufficiency. properties, only vaporizers specifically calibrated for sevoflurane must be used. The administration of general anaesthesia must be individualized based on the patient's response. Hypotension and Sevoflurane produces low levels of Compound A (pentafluoroisopropenyl fluoromethyl ether (PIFE)) respiratory depression increase as anaesthesia is deepened.

> dose-dependent decreases in blood pressure. Excessive decrease in blood pressure may be more with the use of Baralyme rather than Soda lime. (See also Pharmaceutical Precautions.) concentration of Sevoflurane. The recovery from general anaesthesia should be assessed carefully before patients are discharged from the recovery room.

Isolated reports of QT prolongation, very rarely associated with torsade de pointes (in exceptional cases, fatal), have been received. Caution should be exercised when administering sevoflurane to Experience with repeat exposure to Sevoflurane is very limited. However, there were no obvious

Isolated cases of ventricular arrhythmia were reported in paediatric patients with Pompe's disease.

Caution should be exercised in administering general anaesthesia, including sevoflurane, to patients with mitochondrial disorders.

exposures to anaesthetic/ sedative agents early in life. These studies have substantial limitations. myocardial ischemia in patients with coronary artery disease. and it is not clear if the observed effects are due to the anaesthetic/ sedation drug administration or other factors such as the surgery or underlying illness.

Hepatic: Very rare cases of mild, moderate and severe post-operative hepatic dysfunction or hepatitis with or without jaundice have been reported from post-marketing experiences.

Clinical judgment should be exercised when sevoflurane is used in patients with underlying hepatic studied. As with other anaesthetics, small changes in moods may persist for several days following conditions or under treatment with drugs known to cause hepatic dysfunction (see Adverse administration, (see Effects on driving ability and operation of machinery)

the interval is less than 3 months, may increase the potential for hepatic injury.

Malignant Hyperthermia: In susceptible individuals, potent inhalation anesthetic agents may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome Seizures: Rare cases of seizures have been reported in association with sevoflurance use (see known as malignant hyperthermia. The syndrome may include non-specific features such as muscle Warnings and Precautions-Paediatric Use and Adverse Reactions). rigidity, tachycardia, tachypnoea, cyanosis, arrhythmias, and unstable blood pressure. Some of these nonspecific signs may also appear during light anaesthesia, acute hypoxia, hypercapnia,

In clinical trials, one case of malignant hyperthermia was reported. In addition, there have been who may be at risk for seizures, (see Adverse Reactions).

administration of intravenous dantrolene sodium (consult prescribing information for intravenous sevoflurane in paediatric patients with Down syndrome. In most cases, bradycardia improved dantrolene sodium for additional information on patient management), and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory anticholinergic or epinephrine. and circulatory support as indicated, and management of electrolyte-fluid-acid-base abnormalities. Renal failure may appear later, and urine flow should be monitored and sustained if possible.

rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in paediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinyl-choline has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to Sevoflurane may cause respiratory depression, which may be augmented by narcotic premedication malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.

and trace amounts of Compound B (pentafluoromethoxy isopropyl fluoromethyl ether (PMFE)), when in direct contact with CO2 absorbents. Levels of Compound A increase with:- increase in During the maintenance of anaesthesia, increasing the concentration of Sevoflurane produces canister temperature; increase in anaesthetic concentration; decrease in gas flow rate and increase

> In some studies in rats, nephrotoxicity was seen in animals exposed to levels of Compound A in excess of those usually seen in routine clinical practice. The mechanism of this renal toxicity in rats is unknown and its relevance to man has not been established

differences in adverse events between first and subsequent exposures.

General: During maintenance of anaesthesia, increasing the concentration of sevoflurane produces dose-dependent decreases in blood pressure. Excessive decrease in blood pressure may be related to depth of anaesthesia and in such instances may be corrected by decreasing the inspired concentration of sevoflurane

Some published studies in children have observed cognitive deficits after repeated or prolonged As with all anaesthetics, maintenance of hemodynamic stability is important to the avoidance of

The recovery from general anaesthesia should be assessed carefully before patients are discharged from the post-anaesthesia care unit.

Although recovery of consciousness following sevoflurane administration generally occurs within minutes, the impact on intellectual function for two or three days following anaesthesia has not been

Neurosurgery: In patients with normal intracranial pressure (ICP), Sevoflurane had minimal effect It has been reported that previous exposure to halogenated hydrocarbon anaesthetics, especially if on ICP and preserved CO₂ responsiveness. The safety of Sevoflurane has not been investigated in patients with a raised ICP. In patients at risk for elevations of ICP, Sevoflurane should be administered cautiously in conjunction with ICP-reducing manoeuvers such as hyperventilation.

Pediatric Use: The use of sevoflurane has been associated with seizures. Many of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using sevoflurane in patients

Bradycardia in Down Syndrome: Episodes of severe bradycardia and cardiac arrest, not related Treatment of malignant hyperthermia includes discontinuation of triggering agents (eg Sevoflurane), to underlying congenital heart disease, have been reported during anaesthesia induction with with decreasing the concentration of sevoflurane, manipulating the airway, or administering an

> During induction, closely monitor heart rate, and consider incrementally increasing the inspired sevoflurane concentration until a suitable level of anaesthesia is achieved. Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this



34521103_Sojourn250ml_SGP_INS_11_22.indd 1 25/11/2022 12:16:39

Replacement of Desiccated CO2 Absorbents: Rare cases of extreme heat, smoke and/ Sevoflurane, like other inhalational agents, has relaxant effects on the uterus with the potential risk conjunction with the use of desiccated CO₂ absorbent, specifically those containing potassium anaesthesia. hydroxide. An unusually delayed rise or unexpected decline of inspired sevoflurane concentration compared to the vaporizer setting may be associated with excessive heating of the CO₂ absorbent Reproduction studies have been performed in rats and rabbits at doses up to 1 MAC. No effects on

An exothermic reaction, enhanced sevoflurane degradation, and production of degradation products (see "Description and Composition") can occur when the CO₂ absorbent becomes desiccated. Svoflurane should be used during pregnancy only if clearly needed. such as after an extended period of dry gas flow through the CO₂ absorbent canisters. Sevoflurane degradants (methanl, formaldeyde, carbon monoxide, and Compounds A, B, C, and D) were Use in nursing mothers: It is not known whether Sevoflurane or its metabolites is excreted in (≥ 2 hours). Concentrations of formaldehyde observed at the anaesthesia respiratory circuit period. (using sodium hydroxide containing absorbents) were consistent with levels known to cause mild respiratory irritation. The clinical relevance of the degradants observed under this extreme Effects on driving ability and operation of machinery experimental model is unknown.

administration of sevoflurane. The color indicator of most CO₂ absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant color change should not be taken after Sevoflurane anaesthesia. (see Warnings and Precautions) as an assurance of adequate hydration. CO₂ absorbents should be replaced routinely regardless of the state of the color indicator.

Beta-sympathomimetic agents like isoprenaline and alpha- and beta-sympathomimetic agents like adrenaline and noradrenaline should be used with caution during Sevoflurane narcosis, due to a potential risk of ventricular arrhythmia

Non-selective MAO-inhibitors: Risk of crisis during the operation. It is generally recommended that treatment should be stopped 2 weeks prior to surgery.

Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists, in particular dihydropyridine derivaties.

Caution should be exercised when calcium antagonists are used concomitantly with inhalation anesthetics due to the risk of additive negative inotropic effect.

Concomitant use of succinylcholine with inhaled anesthetic agents has been associated with rare All events, at least possibly related to sevoflurane from clinical trials, are displayed in the Table patients during the post-operative period.

The action of non-depolarising muscle relaxants is markedly potentiated with Sevoflurane, therefore, reports. The type, severity, and frequency of adverse events in reference-drug patients. when administered with Sevoflurane, dosage adjustments of these agents should be made

Sevoflurane is similar to isoflurane in the sensitization of the myocardium to the arrhythmogenic effect of exogenously administered adrenaline.

MAC values for Sevoflurane decrease with the addition of nitrous oxide as indicated in the table on 'Effects of age on MAC of Sevoflurane' (see "Dosage and Administration").

As with other agents, lesser concentrations of Sevoflurane may be required following use of an intravenous anaesthetic e.g. propofol.

Medicinal products and compounds that increase the activity of cytochrome P450 isoenzyme CYP2E1 such as isoniazid and alcohol, may increase the metabolism of sevoflurane and lead to significant increase in plasma fluoride concentration. Concomitant use of sevoflurane and isoniazid can potentiate the hepatotoxic effects of isoniazid.

Sevoflurane administration is compatible with barbiturates as commonly used in surgical practice.

Pregnancy and Lactation

Use in pregnancy: With the exception of one study in Caesarean Section, there are no other studies in pregnant women, including in labour and delivery. Experience in Caesarean Section is limited to one trial in a small number of patients. The safety of sevoflurane in labour and vaginal delivery has not been demonstrated

or spontaneous fire in the anesthesia machine have been reported during sevoflurane use in for uterine bleeding. Clinical judgment should be observed when using sevoflurane during obstetric

male and female reproductive capabilities were observed. Reduced foetal body weights concomitant with increased skeletal variations were noted in rats only maternally toxic concentrations. No adverse foetal effects were observed in rabbits. Sevoflurane was not teratogenic. Therefore,

observed in the respiratory circuit of an experimental anaesthesia machine using dessicated human milk. Due to absence of documented experience, women should be advised to skip breast-CO₂ absorbents and maximum sevoflurane concentrations (8%) for extended periods of time feeding for 48 hours after administration of sevoflurane and discard milk produced during this *Occasional cases of transient changes in hepatic function tests were reported with sevoflurane

As with other anaesthetic agents, patients should be advised that performance of activities requiring When a clinician suspects that the CO₂ absorbent may be desiccated, it should be replaced before mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for some time after general anaesthesia. Patients should not be allowed to drive for a suitable period

Adverse Reactions

As with all potent inhaled anaesthetics, Sevoflurane may cause dose-dependent cardiorespiratory depression. Most adverse events are mild to moderate in severity and transient. Nausea, vomiting and sedation drugs that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gammaand delirium are commonly observed in the postoperative period, at a similar incidence to those found with other inhalation anaesthetics. These effects are common sequelae of surgery and general anaesthesia which may be due to the inhalational anaesthetic, other agents administered intraoperatively or post-operatively and to the patient's response to the surgical procedure.

Adverse Reactions Data Derived from Clinical Trials

The most commonly reported adverse reactions were as follows: In adult patients: hypotension, nausea and vomiting

In elderly patients: bradycardia, hypotension and nausea

In paediatric patients: agitation, cough, vomiting and nausea.

increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric below by MedDRA System Organ Class, Preferred Term and frequency. The following frequency groupings are used; very common ($\geq 1/10$); common ($\geq 1/100$ and <1/10); uncommon (\geq 1/1,000 and <1/100); rare ($\ge 1/10,000$ and <1/1,000); very rare (<1/10,000), including isolated

Summary of Most Frequent Adverse Drug Reactions in Sevoflurane Clinical Trials		
System Organ Class	Frequency	Adverse Reactions
Psychiatric disorders	Very common	Agitation
Nervous system disorders	Common	Somnolence Dizziness Headache
Cardiac disorders	Very common Common	Bradycardia Tachycardia
	Uncommon Unknown	Atrioventricular block complete QT prolongation associated with Torsade
Vascular disorders	Very common Common	Hypotension Hypertension
Respiratory, thoracic and mediastinal disorders	Very common Common	Cough Respiratory disorder Laryngospasm
Gastrointestinal disorders	Very common Common	Nausea Vomiting Salivary hypersecretion

General disorders and administration site conditions	Common	Chills Pyrexia
Investigations	Common	Blood glucose abnormal Liver function test abnormal* White blood cell count abnormal Fluoride increased**
Injury, poisoning and procedural complications	Common	Hypothermia

and reference agents.

**Transient increases in serum inorganic fluoride levels may occur during and after sevoflurane anaesthesia

Concentrations of inorganic fluoride generally peak within two hours of the end of sevoflurane anaesthesia and return within 48 hours to pre-operative levels. In clinical trials, elevated fluoride concentrations were not associated with impairment of renal function.

Non-clinical studies/Animal toxicology

Published animal studies of some anaesthetic/sedation drugs have reported adverse effects on brain development in early life and late pregnancy. These studies have demonstrated that anaesthetic aminobutyric acid (GABA) activity during the period of rapid brain growth or synaptogenesis may result in neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis when used for longer than 3 hours. The clinical significance of these non-clinical findings is yet to be determined. However, based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester through the first several months of life, but may extend out to approximately 3 years of age in humans.

Post-Marketing Experience

Adverse events have been spontaneously reported during post-approval use of sevoflurane. The events are reported voluntarily from a population of an unknown rate of exposure. Therefor it is not possible to estimate the true incidence of adverse events or establish a causal relationship to sevoflurane exposure.

Summary of Post-Marketing Adverse Drug Events		
System Organ Class	Adverse Events	
Immune system disorders	Anaphylactic reaction* Anaphylactoid reaction Hypersensitivity*	
Nervous system disorders	Convulsion Dystonia	
Cardiac disorders	Cardiac arrest** Bradycardia in patients with Down syndrom	
Respiratory, thoracic and mediastinal disorders	Bronchospasm Dyspnoea* Wheezing*	
Hepato-biliary disorders	Hepatitis Hepatic failure Hepatic necrosis	
Skin and subcutaneous tissue disorders	Rash* Urticaria Pruritus Dermatitis contact* Swelling face*	
Musculoskeletal and connective tissue disorders	Muscle twitching	
Renal and Urinary disorders	Renal failure acute	

conditions	Chest discomfort*		
* May be associated with hypersensitivity reactions, particularly in association with long-term occupational exposure to inhaled anaesthetic agents.			

** There have been very rare postmarketing reports of cardiac arrest in the setting of sevoflurane use

In the event of overdosage, the following action should be taken: Stop drug administration, establish clear airway and initiate assisted or controlled ventilation with pure oxygen and maintain adequate cardiovascular function

Pharmaceutical precautions: Sevoflurane is chemically stable. As with some halogenated anaesthetics, minor degradation occurs through direct contact with CO2 absorbents. The extent of degradation is clinically insignificant and no dose adjustment or change in clinical practice is necessary when rebreathing circuits are used. Higher levels of Compound A are obtained when using Baralyme rather than Soda lime.

Instructions for use: Some halogenated anaesthetics have been reported to interact with dry carbon dioxide absorbent to form carbon monoxide. To date there is no evidence that this can occur with Sevoflurane. However, in order to minimize the risk of formation of carbon monoxide in re-breathing circuits and the possibility of elevated carboxy-haemoglobin levels, carbon dioxide absorbents should not be allowed to dry out

Package quantities: Sojourn® is packaged in 250 mL amber-coloured glass bottles (with or without an external PVC coating) with either a two component screw-cap or an integrated adaptor multi-component closure.

Further information: The low solubility of Sevoflurane in blood should result in alveolar concentrations which rapidly increase upon induction and rapidly decrease upon cessation of the

In humans <5% of the absorbed Sevoflurane is metabolized. The rapid and extensive pulmonary elimination of Sevoflurane minimizes the amount of anaesthetic available for metabolism. Sevoflurane is defluorinated via cytochrome p450(CYP)2E1 resulting in the production of hexafluoroiso-propanol (HFIP) with release of inorganic fluoride and carbon dioxide (or a one carbon fragment). HFIP is then rapidly conjugated with glucuronic acid and excreted in the urine.

The metabolism of Sevoflurane may be increased by known inducers of CYP2E1 (e.g. isoniazid and alcohol), but it is not inducible by barbiturates.

Transient increases in serum inorganic fluoride levels may occur during and after Sevoflurane anaesthesia. Generally, concentrations of inorganic fluride peak within 2 hours of the end of Sevoflurane anaesthesia and return within 48 hours to pre-operative levels.

Special Precautions for storage: Do not store above 30°C. Do not refrigerate.

Keep bottle cap tightly closed due to the volatile nature of the anaesthetic. Store the bottle in an upright position.



© 2022 Piramal Critical Care, Inc.

34521103

34521103_Sojourn250ml_SGP_INS_11_22.indd 2 25/11/2022 12:16:40